search

Active clinical trials for "Thyroid Neoplasms"

Results 621-630 of 654

Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy...

Hypothyroidism

The incidence of differentiated thyroid cancer is increasing in Korea. A significant number of them experience severe hypothyroidism in preparation for radioactive iodine (RAI) therapy after total thyroidectomy. Because the function of thyroid hormone is closely linked with lipid and glucose metabolism, overt hypothyroidism after thyroid hormone withdrawal during RAI therapy may induce the changes of metabolic parameters. We investigate the effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer.

Unknown status7 enrollment criteria

Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels

Thyroid CancerBreast Cancer

Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy patients.

Unknown status2 enrollment criteria

Lateral Neck Lymph Node Mapping in Thyroid Cancer

Thyroid Cancer

This study includes papillary thyroid cancer patients who have unpalpable lateral neck lymph nodes but suspicious on ultrasound and/or CT. Carbon nanoparticles is used as the tracer for lateral neck lymph node mapping.

Unknown status7 enrollment criteria

Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy...

Thyroid CancerThyroidectomy With Central Lymph Node Dissection

The aim of the study is to evaluate the effectiveness of autofluorescence in the intraoperative preservation of parathyroids during total thyroidectomy with central lymph node compartment dissection.

Unknown status8 enrollment criteria

Thyroid Cancer and (FDG)PET/CT Scan

Thyroid Cancer

Background and Rational (Introduction) Differentiated thyroid carcinoma (DTC) have favorable prognosis. Overall 10-year survival is 93% for papillary carcinoma, and 85% for follicular carcinoma(1). After total thyroidectomy followed by radioiodine remnant ablation, DTC patients are screened for recurrence by measuring the levels of both Tg and TgAb and I-131 whole body scan (WBS) in the follow-up (2) It is reported that elevated TgAb may indicate the recurrent and/or metastatic disease and can be used as an alternative of the tumor marker for DTC . The I-131 WBS has high specificity to detect recurrence (50 to 60% in papillary thyroid carcinoma and 64 to 67% in follicular thyroid carcinoma) (3,4). The I-131WBS showed negative finding in 10 to 15% of patients with detectable serum Tg levels(5). Two factors may account for discrepancy between serum Tg and I-131 WBS . First, the tumor size might be too small to be detected by WBS. Second, the tumor cell may lose the ability to trap radioiodine while still able to secret Tg(6,7). It becomes necessary to investigate with other modalities to identify possible residual disease to initiate the appropriate treatment. (8) Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. (9) The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. (10) It is a valuable tool for staging and re staging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques.(11) Aim of the study The aim of this study was to evaluate the diagnostic accuracy of (PET/CT) in patients with suspected thyroid cancer recurrence or metastasis , with differentiated thyroid cancer (DTC) patients who show elevated serum thyroglobulin (Tg) or antithyroglobulin antibody (TgAb) level with negative radioiodine whole body scan (I-WBS).

Unknown status6 enrollment criteria

PET Evaluation of Recurrent Differentiated Thyroid Cancer

Thyroid NeoplasmsDifferentiated Thyroid Cancer

After initial treatment of differentiated thyroid cancer patients (DTC) are followed by a blood test, a biomarker called thyroglobulin, in order to detect a possible recurrence. Nowadays patients are treated 'blindly' with high dose radioactive iodine to treat a suspected recurrence. However, the scan made after therapy to verify the effect of the treatment shows that in up to 50% the treatment could be considered as futile. 124I - a radioactive isotope - in combination with whole body PET became recently available for use in the follow-up of DTC. This could make it possible before the therapy with high dose radioactive iodine to determine the extensiveness of the disease and whether effect of the therapy could be expected. Additionally, recurrent DTC lesions that do not accumulate iodine can be found without the futile treatment with 131I. FDG-PET (another PET modality) is able to detect these lesions. The value of FDG-PET before 131I treatment however has not been tested. The combination of these two diagnostic tools, 124I-PET and FDG-PET, has a potential to allow earlier and better restaging and selection for treatment

Unknown status10 enrollment criteria

The Role of Midkine in Diagnosis of Thyroid Cancer

Thyroid Cancer

Evaluation of the role of serum midkine in differentiating malignant from benign thyroid nodule studying the level of serum midkine in relation to different thyroid cancer stages

Unknown status4 enrollment criteria

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)...

Thyroid Cancer

It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %. The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.

Unknown status6 enrollment criteria

Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional...

Thyroid Cancer

To explore how a clinical sample of patients with thyroid nodules (men and women) with no history of thyroid cancer would make decisions about treatments based on different terminology used to describe papillary thyroid cancer (with and without the cancer term).

Withdrawn2 enrollment criteria

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated...

Differentiated Thyroid Cancer

This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.

Approved for marketing27 enrollment criteria
1...626364...66

Need Help? Contact our team!


We'll reach out to this number within 24 hrs